Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, ...

Pure autonomic failure may serve as a prodromal manifestation of Parkinson disease, Lewy body dementia, and multiple system atrophy.

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Alterity Therapeutics Limited ATHE stock is up during Tuesday’s session as the biotechnology company announced an ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

In the Phase 2 study, the incidence of treatment-emergent adverse events was similar to placebo, and no unexpected safety signals were identified In mUMSARS scores and MRI-based brain volume ...

Detailed price information for Alterity Therapeutics Ltd ADR (ATHE-Q) from The Globe and Mail including charting and trades.

A new MRI marker showed high accuracy for progressive supranuclear palsy diagnosis across international cohorts. Find out more.

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.